FDA reviewers mull surrogate endpoint for Intercept's OCA

FDA reviewers questioned the utility of alkaline phosphatase (ALP) as a surrogate endpoint for approval of obeticholic acid ( OCA; DSP-1747) from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) to treat primary biliary cholangitis (PBC), but appeared amenable to its use. The

Read the full 393 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE